
News|Articles|March 1, 2002
Arixtra (Fondaparinux sodium injection), Organon/Sanofi-Synthelabo
New biologic: Factor Xa inhibitor for reducing risk of blood clotsafter orthopedic surgeries
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Advancing Equity and Access in Breast Cancer Care
2
Type 1 Diabetes Drug Tzield Under Expedited Review Through New FDA Program
3
Jury Still Out on Effect of GLP-1 Drugs on the Eyes | AAO 2025
4
Cobenfy in Practice: Hope, Hurdles, and the Next Chapter in Schizophrenia Care
5